Current Clinical Trials

Standard treatment options for female/male recurrent urethral cancer:

1. Locally recurrent urethral cancer after radiation therapy should be treated by surgical excision.
2. Locally recurrent urethral cancer after surgery alone should be considered for combination radiation and wider surgical resection.[1]

Treatment options under clinical evaluation:

• Metastatic urethral cancer should be considered for clinical trials using chemotherapy. Early evidence suggests that transitional cell cancer of the urethra may respond favorably to the same chemotherapy regimens employed for advanced transitional cell cancer of the bladder.

Check for U.S. clinical trials from NCI's PDQ Cancer Clinical Trials Registry that are now accepting patients with recurrent urethral cancer ¹. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.

General information about clinical trials is also available from the NCI Web site ².

References

1. Scher HI, Yagoda A, Herr HW, et al.: Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for extravesical urinary tract tumors. J Urol 139 (3): 475-7, 1988.  [PUBMED Abstract]